<SEC-DOCUMENT>0001104659-21-010551.txt : 20210202
<SEC-HEADER>0001104659-21-010551.hdr.sgml : 20210202
<ACCEPTANCE-DATETIME>20210202081152
ACCESSION NUMBER:		0001104659-21-010551
CONFORMED SUBMISSION TYPE:	S-3ASR
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20210202
DATE AS OF CHANGE:		20210202
EFFECTIVENESS DATE:		20210202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3ASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-252646
		FILM NUMBER:		21579087

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3ASR
<SEQUENCE>1
<FILENAME>tm214628d3_s3asr.htm
<DESCRIPTION>S-3ASR
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities </B>and
<B>Exchange Commission on February 2, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMICUS THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 49%; font-size: 10pt; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; font-size: 10pt; text-align: center"><B>71-0869350</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(State of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer<BR>
Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3675 Market Street <BR>
Philadelphia, PA 19104<BR>

(215) 921-7600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone
number, including area code, of Registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>John F. Crowley<BR>
Chief Executive Officer<BR>
Amicus Therapeutics,&nbsp;Inc.<BR> 3675 Market Street <BR>
Philadelphia, PA 19104 <BR>
(215) 921-7600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and
telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Approximate date of commencement of proposed
sale to the public:<BR>
From time to time after the effective date of this Registration Statement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the only securities being registered
on this Form&nbsp;are being offered pursuant to dividend or interest reinvestment plans, please check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered
on this Form&nbsp;are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933,
other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is filed to register
additional securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is a post-effective amendment
filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is a registration statement
pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule&nbsp;462(e)&nbsp;under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes
of securities pursuant to Rule&nbsp;413(b)&nbsp;under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
accelerated filer&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
filer&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 29%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Smaller
        reporting company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
        growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<BR>
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of Securities
Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 2.5pt double">CALCULATION OF REGISTRATION FEE</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Title
                                         of Each Class&nbsp;of Securities</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>to
                                         be Registered(1)</B></P></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B><I>&nbsp;</I></B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amount
                                         to be</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registered(2)</B></P></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B><I>&nbsp;</I></B></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B><I>&nbsp;</I></B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Proposed
                                         Maximum</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Offering
                                         Price Per</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share(3)</B></P></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B><I>&nbsp;</I></B></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B><I>&nbsp;</I></B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Proposed
                                         Maximum</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Aggregate
                                         Offering</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Price(3)</B></P></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B><I>&nbsp;</I></B></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B><I>&nbsp;</I></B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amount
                                         of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration
                                         Fee(4)</B></P></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B><I>&nbsp;</I></B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif">Common Stock, $0.01 par value per share, underlying warrants</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,554,999</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">19.145</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">48,915,455.86</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,336.68</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;All shares of common stock registered hereby consist of shares of common stock that may be acquired upon exercise of warrants. Such shares of common stock are offered for the account of certain selling stockholders.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;Pursuant to Rule&nbsp;416 under the securities act of 1933, as amended (the &ldquo;Securities Act&rdquo;), this registration statement also covers an indeterminate number of additional shares of common stock as may be issuable with respect to the shares being registered hereunder as a result of a stock split, stock dividend, recapitalization or other similar event.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)&nbsp;&nbsp;&nbsp;Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule&nbsp;457(c)&nbsp;under the Securities Act, based upon the average of the high and low prices of the registrant&rsquo;s common stock on January&nbsp;27, 2021, as reported on the NASDAQ Global Market.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.25in; font-size: 10pt">(4)&nbsp;&nbsp;&nbsp;A filing fee of $5,336.68 was
    previously paid in connection with Amicus Therapeutics, Inc.&rsquo;s January 29, 2021 filing of a registration statement on
    Form S-3 (File No. 333-252566), which filing was subsequently withdrawn by a registration withdrawal request made on February
    2, 2021. In accordance with Rule 457(p) of the Securities Act, such previously paid filing fee will offset the filing fee of
    $5,336.68 currently due pursuant to this registration statement.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMICUS THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm214628d3_s3asrimg001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2,554,999 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus relates to the resale of up to 2,554,999 shares
of common stock, par value $0.01 per share of Amicus Therapeutics,&nbsp;Inc. that are underlying warrants, by the selling stockholders
identified beginning on page&nbsp;7 of this prospectus, together with any additional selling stockholders identified in
any applicable prospectus supplement. The selling stockholders acquired the warrants to acquire these shares from us in connection
with a Note and Warrant Purchase Agreement, dated as of February&nbsp;19, 2016 (the &ldquo;February&nbsp;2016 Purchase Agreement&rdquo;),
and a subsequent Joinder to and Amendment of Note and Warrant Purchase Agreement, dated as of June&nbsp;30, 2016, (the &ldquo;Amended
Purchase Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are not selling any shares of our common stock under this
prospectus and we will not receive any of the proceeds from the sale of shares by the selling stockholders. The selling stockholders
may sell the shares of common stock described in this prospectus through public or private transactions at market prices prevailing
at the time of sale or at negotiated prices. Additional information about how the selling stockholders may sell their shares of
common stock is provided in the section of this prospectus entitled &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the NASDAQ Global Market under
the symbol &ldquo;FOLD.&rdquo; On January&nbsp;29, 2021, the last reported sale price for our common stock on the NASDAQ Global
Market was $18.91 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our common stock involves a high degree of risk.
You should review carefully the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; beginning on page&nbsp;4
of this prospectus and under similar headings in the other documents filed with the Securities and Exchange Commission that are
incorporated by reference in this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prospectus dated February 2, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%"><A HREF="#S1_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: right; width: 10%"><A HREF="#S1_001">1</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_002">2</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_003">4</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_005">6</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELLING STOCKHOLDERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_006">7</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_007">8</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS </FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#S1_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#S1_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are responsible for the information contained and incorporated
by reference in this prospectus, any accompanying prospectus supplement and in any related free writing prospectus we prepare or
authorize. We have not authorized anyone to provide you with any other information, and we take no responsibility for any other
information that others may provide you. This prospectus and any accompanying prospectus supplement do not constitute an offer
to sell, or a solicitation of an offer to purchase, any securities other than the registered securities to which they relate, nor
do this prospectus and any accompanying prospectus supplement constitute an offer to sell, or a solicitation of an offer to purchase,
the securities offered hereby, or thereby in any jurisdiction to or from any person whom or from whom it is unlawful to make such
offer or solicitation of an offer in such jurisdiction. The information appearing or incorporated by reference in this prospectus,
any accompanying prospectus supplement, and any related free writing prospectus, is accurate only as of the date thereof, regardless
of the time of delivery of this prospectus, any accompanying prospectus supplement, or any related free writing prospectus, or
of any sale of our securities. Our business, financial condition, and results of operations may have changed since those dates.
It is important for you to read and consider all the information contained in this prospectus and in any accompanying prospectus
supplement, including the documents incorporated by reference herein or therein, before making your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of an automatic shelf registration statement
that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), as a &ldquo;well-known seasoned issuer&rdquo;
as defined in Rule&nbsp;405 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), utilizing a &ldquo;shelf&rdquo;
registration process. Under this process, selling stockholders named in this prospectus or in one or more supplements to this prospectus
may offer or sell shares of our common stock, as described in this prospectus, in one or more offerings from time to time. Each
time any selling stockholder not named in this prospectus (or in any supplement to this prospectus) sells shares of common stock
under the registration statement of which this prospectus is a part, such selling stockholder must provide a copy of this prospectus
and any applicable prospectus supplement, to a potential purchaser, as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may also authorize one or more free writing prospectuses
or prospectus supplements to be provided to you in connection with these offerings. Any related free writing prospectus or prospectus
supplement may also add, update or change information contained in this prospectus or in any documents that we have incorporated
by reference into this prospectus and, accordingly, to the extent inconsistent, information in this prospectus is superseded by
the information in any prospectus supplement or any related free writing prospectus and any documents incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may offer and sell shares of our common
stock directly to purchasers through agents selected by the selling stockholders, or to or through underwriters or dealers. A prospectus
supplement, if required, may described the terms of the plan of distribution and set forth the names of any agents, underwriters
or dealers involved in the sale of shares of our common stock. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read this prospectus together with any applicable
prospectus supplement, as well as additional information described under the heading &ldquo;Where You Can Find More Information.&rdquo;
You should only rely on the information contained or incorporated by reference in this prospectus, and any applicable prospectus
supplement or any related free writing prospectus that we may authorize to be provided to you. We have not authorized, and no selling
stockholder has authorized, any other person to provide you with different or additional information. If anyone provides you with
different or inconsistent information, you should not rely on it. No offer of shares of common stock is being made in any jurisdiction
where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should not assume that the information in this prospectus,
any applicable prospectus supplement, any related free writing prospectus or any document incorporated by reference herein or therein
is accurate as of any date other than the date on the cover of the applicable document. Our business, financial condition, results
of operations and prospects may have changed since those dates. We urge you to read carefully this prospectus, the documents incorporated
by reference in this prospectus, any applicable prospectus supplement and any applicable free writing prospectus before making
an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Unless the context requires otherwise, references in this
prospectus to &ldquo;the Company,&rdquo; &ldquo;Amicus,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us,&rdquo; and other
similar terms mean Amicus Therapeutics,&nbsp;Inc. and our wholly owned subsidiaries.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<DIV STYLE="border: Black 1pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_002"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This summary highlights selected information contained elsewhere
or incorporated by reference into this prospectus, and does not contain all the information that you should consider before investing
in our common stock. You should carefully read the entire prospectus, including the risks of investing on our common stock discussed
under the heading &ldquo;Risk Factors&rdquo; on page&nbsp;4 of this prospectus and under similar headings in the other documents
that are incorporated by reference herein.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a global, patient-dedicated biotechnology company focused
on discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio of product opportunities led
by our novel medicine for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease
in the clinic, and an industry leading rare disease gene therapy portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The cornerstone of our portfolio is Galafold&reg; (also referred
to as &ldquo;migalastat&rdquo;), the first and only approved oral precision medicine for people living with Fabry disease who have
amenable genetic variants. Migalastat is currently approved under the trade name Galafold&reg; in the United States (&ldquo;U.S.&rdquo;),
European Union, United Kingdom, and Japan, with multiple additional approvals granted and applications pending in several geographies
around the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The lead biologics program of our pipeline is Amicus Therapeutics
GAA (&ldquo;AT-GAA&rdquo;, also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for
Pompe disease. In February&nbsp;2019, the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) granted Breakthrough Therapy designation
to AT-GAA for the treatment of late onset Pompe disease. In the first quarter of 2020, the British Medicines and Healthcare Products
Regulatory Agency issued a Promising Innovative Medicine designation for AT-GAA for the treatment of late-onset Pompe disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have established an industry leading gene therapy portfolio
of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital and
an expanded collaboration with the University of Pennsylvania (&ldquo;Penn&rdquo;). Our pipeline includes gene therapy programs
in rare, neurologic lysosomal disorders (&ldquo;LDs&rdquo;), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease,
Fabry disease, CDKL5 deficiency disorder, Mucopolysaccharidosis Type IIIB (&ldquo;MPS IIIB&rdquo;), as well as a next generation
program in Mucopolysaccharidosis Type IIIA (&ldquo;MPS IIIA&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This expanded collaboration with Penn also provides us with
exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and
programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic
Dystrophy, and select other muscular dystrophies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the first quarter of 2020, the FDA granted Fast Track designation
to the CLN3 Batten disease gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age. In September&nbsp;2020,
the European Medicines Agency granted Priority Medicines designation to the CLN6 Batten disease gene therapy, AT-GTX-501, for the
treatment of patients with variant late infantile neuronal ceroid lipofuscinosis 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We were incorporated under the laws of the State of
Delaware on February&nbsp;4, 2002. Our global headquarters are located at 3675 Market Street, Philadelphia, PA 19104 and our
telephone number is (215) 921-7600. Our website address is www.amicusrx.com. We make available free of charge on our website
our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably practicable after we
electronically file such material with, or furnish such material to, the SEC. Information contained on our website is not
incorporated by reference into this prospectus, and you should not consider information contained on our website as part of
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Throughout this prospectus, when we refer to the shares of our
common stock, the offer and sale of which are being registered on behalf of the selling stockholders on the registration statement
of which this prospectus is a part, we are referring to the shares of common stock underlying warrants held by the Purchasers,
as defined in the February&nbsp;2016 Purchase Agreement and the Amended Purchase Agreement (the &ldquo;Purchasers&rdquo;). When
we refer to the &ldquo;selling stockholders&rdquo; in this prospectus, we are referring to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock offered by the selling stockholders</B></FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,554,999 shares underlying warrants to purchase common stock</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of Proceeds</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All shares of common stock offered hereby are being sold by the selling stockholders. Accordingly, we will not receive any proceeds from the sale of these shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An investment in our common stock involves a high degree of risk. See the information contained in or incorporated by reference under &ldquo;Risk Factors&rdquo; on page&nbsp;4 of this prospectus and under similar headings in the other documents that are incorporated by reference herein, as well as the other information included in or incorporated by reference in this prospectus.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASDAQ Global Market symbol</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is quoted and traded on the NASDAQ Global Market under the symbol &ldquo;FOLD.&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_003"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing in our common stock involves risks. Prior to making
a decision about investing in our securities, you should carefully consider the specific factors discussed below and any factors
discussed under the heading &ldquo;Risk Factors&rdquo; in any prospectus supplement, together with all of the other information
contained or incorporated by reference in this prospectus or any prospectus supplement. You should also consider the risks, uncertainties
and assumptions discussed under the heading &ldquo;Risk Factors&rdquo; in our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000015/amicus1231201910-k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2019, filed on March&nbsp;2, 2020</A>, with the SEC, and our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000035/fold-20200930.htm" STYLE="-sec-extract: exhibit">quarterly report on Form&nbsp;10-Q for the period ended September&nbsp;30, 2020, filed on November&nbsp;5, 2020</A>, with the SEC, each of which is incorporated herein by reference,
and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks
and uncertainties we have described therein and below are not the only risks that we face. Additional risks and uncertainties not
presently known to us or that we currently deem immaterial may also affect our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_004"></A>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus and the documents incorporated by reference
herein contain, and any prospectus supplement and the documents incorporated by reference therein may contain, forward-looking
statements that involve risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements
of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by,
followed by, or include the words &ldquo;aim,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;can,&rdquo; &ldquo;could,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;forecast,&rdquo; &ldquo;intend,&rdquo; &ldquo;likely,&rdquo; &ldquo;may,&rdquo;
 &ldquo;outlook,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;seek,&rdquo;
 &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; the negatives or plurals thereof, and other words and terms of similar
meaning, although not all forward-looking statements contain these identifying words.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have based these forward-looking statements on our current
expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking
statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand
that the following important factors could affect our future results and could cause those results or other outcomes to differ
materially from those expressed or implied in our forward-looking statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the progress and results of our preclinical and clinical trials of our drug candidates and gene therapy candidates, including
but not limited to AT-GAA, CLN6 and CLN3;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme
Replacement Therapy (ERT or ATB200 or cipaglucosidase alfa) and gene therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the scope, progress, results, and costs of preclinical development, laboratory testing, and clinical trials for our product
candidates including those testing the use of a pharmacological chaperone co-administered with ERT for the treatment of Pompe disease
(AT-GAA) and gene therapies for the treatment of rare genetic metabolic diseases;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the future results of on-going preclinical research and subsequent clinical trials for CDKL5 deficiency disorder, Pompe gene
therapy, Fabry gene therapy, MPS IIIB and next generation MPS IIIA, including our ability to obtain regulatory approvals and commercialize
these gene therapies and obtain market acceptance for such therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs, timing, and outcome of regulatory review of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any changes in regulatory standards relating to the review of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number and development requirements of other product candidates that we pursue;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs of commercialization activities, including product marketing, sales, and distribution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the emergence of competing technologies and other adverse market developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to successfully commercialize Galafold&reg; (also referred to as &ldquo;migalastat HCl&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to manufacture or supply sufficient clinical or commercial products, including Galafold&reg;, AT-GAA and our gene
therapy candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to obtain reimbursement for Galafold&reg;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold&reg;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to obtain market acceptance of Galafold&reg;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual
property-related claims;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which we acquire or invest in businesses, products, and technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to successfully integrate our acquired products and technologies into our business, including the possibility that
the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to establish collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other
payments from any such collaborators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to adjust to changes in the European and United Kingdom markets in the wake of the United Kingdom leaving the European
Union;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which our business could be adversely impacted by the effects of the novel coronavirus (&ldquo;COVID-19&rdquo;)
outbreak, including due to actions by us, governments, our customers or suppliers or other third parties to control the spread
of COVID-19, or by other health epidemics or pandemics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fluctuations in foreign currency exchange rates; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in accounting standards.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In light of these risks and uncertainties, we may not actually
achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations
disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in
this prospectus, particularly those incorporated by reference in the section captioned &ldquo;Risk Factors&rdquo; that we believe
could cause actual results or events to differ materially from the forward-looking statements that we make. Those factors and the
other risk factors described therein are not necessarily all of the important factors that could cause actual results or developments
to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also
could harm our results. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers,
dispositions, joint ventures, collaborations, or investments we may make. Consequently, there can be no assurance that actual results
or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences
to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read this prospectus and the documents that we incorporate
by reference herein completely and with the understanding that our actual future results may be materially different from what
we expect. These forward-looking statements speak only, as applicable, as of the date of this prospectus, any prospectus supplement
or the documents incorporated by reference therein. We undertake no obligation, and specifically decline any obligation, to publicly
update or revise any forward-looking statements, even if experience or future developments make it clear that projected results
expressed or implied in such statements will not be realized, except as may be required by law. Before deciding to purchase our
securities, you should carefully consider the risk factors discussed and incorporated by reference in this prospectus and in the
registration statement of which this prospectus is a part.<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_005"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders will make offers and sales pursuant
to this prospectus and any applicable prospectus supplement. We will not receive any proceeds from the sale or other disposition
by the selling stockholders of the shares of our common stock covered hereby, or interests therein. The selling stockholders will
pay any expenses incurred for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders
in disposing of these shares. We will bear all other costs, fees and expenses incurred in effecting the registration statement
of which this prospectus forms a part, including, without limitation, all registration fees, listing fees of the NASDAQ Global
Market and fees and expenses of our counsel and our accountants.<BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_006"></A>SELLING
STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are registering for resale an aggregate of 2,554,999 shares
of our common stock that may be acquired upon exercise of warrants and that may be sold by the selling stockholders set forth herein.
The shares registered hereby underly warrants issued to the Purchasers in connection with the sale of notes and warrants pursuant
to the February&nbsp;2016 Purchase Agreement and the Amended Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Section&nbsp;7.1 of the February&nbsp;2016 Purchase
Agreement, we agreed to file with the SEC, a registration statement, or prospectus supplement under an existing &ldquo;shelf&rdquo;
registration statement, to register for resale the shares of our common stock underlying warrants that we issued as part of the
consideration for the purchase of promissory notes. We agreed to use reasonable best efforts to keep such registration statement
effective until the earlier of (i)&nbsp;the date on which all such shares of common stock have been sold pursuant to such registration
statement, (ii)&nbsp;at such time as all such shares of common stock can be freely sold without volume limitations pursuant to
Rule&nbsp;144 of the Securities Act (including at such times as the holder may be deemed to be an affiliate of the Company at the
time of resale), and (iii)&nbsp;twenty-four calendar months from the date of effectiveness of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficial ownership is determined in accordance with the rules&nbsp;of
the SEC, and includes voting or investment power with respect to our common stock. Except as indicated by the footnotes below,
we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment
power with respect to all shares of common stock that they beneficially own, subject to applicable community property laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may sell some, all or none of their
respective shares of common stock offered by this prospectus from time to time. We do not know how long the selling stockholders
will hold their respective shares of common stock covered hereby before selling them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Shares Beneficially</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Number of</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Shares Beneficially</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Owned Prior to</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; font-size: 10pt"><B>Shares Being</B></TD><TD STYLE="white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Owned After the</B></TD><TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>the Offering</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>Registered
                                         for</B></P></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Offering</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><B>Name of Selling Stockholder</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Shares(3)</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Percentage(4)</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-size: 10pt"><B>Resale(5)</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Shares(6)</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Percentage(4)</B></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: left">REDMILE GROUP, LLC (1)</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">22,125,489</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">8.523</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,504,999</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">20,620,490</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">7.943</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GCM GROSVENOR SPECIAL OPPORTUNITIES MASTER FUND,&nbsp;LTD. (2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,050,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,050,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; padding-left: 18.75pt; text-indent: -18.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents less than 1% of the total aggregate amount of shares of our common stock </FONT></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 18.75pt; text-indent: -18.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;Redmile Group, LLC shares voting power and investment power in the shares hereby registered with certain private investment vehicles and separately managed accounts that it manages, as follows: Redmile Capital Fund, LP (374,517 shares underlying warrants to purchase common stock); Redmile Capital Offshore II Master Fund,&nbsp;Ltd. (577,889 shares underlying warrants to purchase common stock); Redmile Capital Offshore Master Fund,&nbsp;Ltd. (502,055 shares underlying warrants to purchase common stock); and Redmile Strategic Master Fund, LP (50,538 shares underlying warrants to purchase common stock). Redmile Group, LLC is the investment manager/ adviser to such private investment vehicles and, in such capacity, may be deemed to be the
beneficial owner of these securities. Jeremy C. Green serves as the managing member of Redmile Group, LLC and also may be deemed to be
the beneficial owner of these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the
extent of its or his pecuniary interest in such shares, if any.</FONT></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.75pt; text-indent: -18.75pt">(2)&nbsp;&nbsp;&nbsp;GCM
        Grosvenor Special Opportunities Master Fund,&nbsp;Ltd. has sole voting and investment power over the shares.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.75pt; text-indent: -18.75pt">(3)&nbsp;&nbsp;&nbsp;Includes shares
        underlying warrants to purchase common stock.</P></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 18.75pt; text-indent: -18.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)&nbsp;&nbsp;&nbsp;Based on 259,600,650 shares outstanding as of September&nbsp;30, 2020. </FONT></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 18.75pt; text-indent: -18.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)&nbsp;&nbsp;&nbsp;Represents the number of shares being registered on behalf of the selling stockholder pursuant to the registration statement, of which this prospectus forms a part, which may be less than the total number of shares beneficially owned by such selling stockholder. </FONT></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 18.75pt; text-indent: -18.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)&nbsp;&nbsp;&nbsp;Assumes the selling stockholders dispose of all of the shares of common stock covered by this prospectus and do not acquire beneficial ownership of any additional shares. The registration of these shares does not necessarily mean that the selling stockholders will sell all or any portion of the shares covered by this prospectus.</FONT></TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_007"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders and any of their pledgees, assignees
and successors-in-interest may, from time to time in one or more transactions on NASDAQ or any other organized market where our
shares of common stock may be traded, sell any or all of their shares of our common stock offered hereby through underwriters,
dealers or agents, directly to one or more purchasers or through a combination of any such methods of sale. The selling stockholders
may distribute the shares of our common stock offered hereby from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at a fixed price or prices, which may be changed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at market prices prevailing at the time of sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at prices related to such prevailing market prices; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at negotiated prices.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may use any one or more of the following
methods when selling the shares offered hereby:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the over-the-counter market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in transactions otherwise than on these exchanges or systems or in the over-the-counter market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through the writing or settlement of options, whether such options are listed on an options exchange or otherwise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>one or more block trades in which the broker-dealer will attempt to sell the shares as agent or principal of all such shares
held by the selling stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an exchange distribution in accordance with the rules&nbsp;of the applicable exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>privately negotiated transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>short sales;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>agreements between broker-dealers and the selling stockholder to sell a specified number of such shares at a stipulated price
per share; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other method or combination of methods of sale permitted pursuant to applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may also sell shares pursuant to Rule&nbsp;144
under the Securities Act, if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the selling stockholders effect such transactions by selling
shares of common stock offered hereby to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or
agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions
from purchasers of the shares of common stock offered hereby for whom they may act as agent or to whom they may sell as principal
(which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those
customary in the types of transactions involved). In connection with sales of the shares of common stock offered hereby or otherwise,
the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the
shares of common stock offered hereby in the course of hedging in positions they assume. The selling stockholders may also sell
shares of common stock offered hereby short and deliver shares of common stock covered by this prospectus to close out short positions
and to return borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge shares of common
stock offered hereby to broker-dealers that in turn may sell such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may from time to time pledge or grant
a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their
secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this
prospectus or any amendment to this prospectus under Rule&nbsp;424(b)(3), or other applicable provision of the Securities Act,
supplementing or amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors
in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock
in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial
owners for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders and any broker-dealer participating
in the distribution of the shares of common stock offered hereby may be deemed to be &ldquo;underwriters&rdquo; within the meaning
of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and
any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Any such discounts, concessions, commissions and similar selling expenses, if any, attributable to the
sale of shares will be borne by a selling stockholder. The selling stockholders may agree to indemnify any agent, dealer or broker-dealer
that participates in transactions involving sales of the shares if liabilities are imposed on that person under the Securities
Act. At the time a particular offering of the shares of common stock offered hereby is made, a prospectus supplement, if required,
will be distributed which will set forth the aggregate amount of shares of common stock being offered and the terms of the offering,
including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation
from the selling stockholders and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the securities laws of some states, the shares of common
stock offered hereby may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states
the shares of common stock offered hereby may not be sold unless such shares have been registered or qualified for sale in such
state or an exemption from registration or qualification is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurance that any selling stockholder will
sell any or all of the shares of common stock registered pursuant to the registration statement, of which this prospectus forms
a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders and any other person participating
in such distribution will be subject to the applicable provisions of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), and the rules&nbsp;and regulations promulgated thereunder, including, without limitation, Regulation M of the Exchange
Act, which may limit the timing of purchases and sales of any of the shares of common stock offered hereby by the selling stockholders
and any other participating person. Regulation M may also restrict the ability of any person engaged in the distribution of the
shares of common stock offered hereby to engage in market-making activities with respect to the shares of common stock offered
hereby. All of the foregoing may affect the marketability of the shares of common stock offered hereby and the ability of any person
or entity to engage in market-making activities with respect to the shares of common stock offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Once sold under the shelf registration statement, of which this
prospectus forms a part, the shares of common stock will be freely tradable in the hands of persons other than our affiliates.<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_008"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of the shares of common stock offered by this prospectus
has been passed upon for Amicus by Troutman Pepper Hamilton Sanders LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_009"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ernst&nbsp;&amp; Young LLP, independent registered public accounting
firm, has audited our consolidated financial statements included in our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000015/amicus1231201910-k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019</A>, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2019, as set forth in their
reports, which are incorporated by reference in this prospectus and elsewhere in this registration statement. Our consolidated
financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&rsquo;s report, given on their authority
as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_010"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of the registration statement on Form&nbsp;S-3
we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement.
Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be
complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other
documents incorporated herein by reference for a copy of such contract, agreement or other document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We file annual, quarterly and current reports, proxy statements
and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the
SEC's website at www.sec.gov. We also maintain a website at amicusrx.com, at which you may access these materials free of charge
as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on,
or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider
such information contained on, or accessed through, our website as part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, you may request copies of these filings at no cost,
by writing or telephoning us at the following address or telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">Office
of the Corporate Secretary<BR>
Amicus Therapeutics,&nbsp;Inc.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3675 Market Street <BR>
Philadelphia, PA 19104<BR>
 (215) 921-7600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="S1_011"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information into this prospectus. This means that we can disclose important information to you by referring you to other documents
we have filed separately with the SEC, without actually including the specific information in this prospectus. The information
incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC (and that
is deemed to be &ldquo;filed&rdquo; with the SEC) will automatically update, and may supersede, information in this prospectus.
We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information
or documents listed below that we have filed with the SEC (Commission File No.&nbsp;001-33497):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000015/amicus1231201910-k.htm" STYLE="-sec-extract: exhibit">Our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;2, 2020;</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000110465920051057/tm201947-4_def14a.htm" STYLE="-sec-extract: exhibit">The information specifically incorporated by reference into our Annual Report on Form&nbsp;10-K from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April&nbsp;4, 2020;</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Quarterly Reports on Form&nbsp;10-Q for the quarters ended March&nbsp;31, 2020, filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000023/fold-20200331.htm" STYLE="-sec-extract: exhibit">May&nbsp;7, 2020</A>,
June&nbsp;30, 2020, filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000033/fold-20200630.htm" STYLE="-sec-extract: exhibit">August&nbsp;10, 2020</A>, and September&nbsp;30, 2020, filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000035/fold-20200930.htm" STYLE="-sec-extract: exhibit">November&nbsp;5, 2020</A>;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Current Reports on Form&nbsp;8-K, as filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000002/form8-k1720.htm" STYLE="-sec-extract: exhibit">January&nbsp;7, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000004/form8-k1820.htm" STYLE="-sec-extract: exhibit">January&nbsp;9, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465920003211/tm202192-1_8k.htm" STYLE="-sec-extract: exhibit">January&nbsp;13, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000006/form8-k2620.htm" STYLE="-sec-extract: exhibit">February&nbsp;7, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000010/form8-k21220.htm" STYLE="-sec-extract: exhibit">February&nbsp;12, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000017/fold-20200323.htm" STYLE="-sec-extract: exhibit">March&nbsp;23, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465920058375/tm2019068d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;8, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465920061142/tm2019068-3_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;14, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000025/fold-20200604.htm" STYLE="-sec-extract: exhibit">June&nbsp;8, 2020</A>,
<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887920000029/fold-20200717.htm" STYLE="-sec-extract: exhibit">July&nbsp;17, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465920088407/tm2026191d1_8k.htm" STYLE="-sec-extract: exhibit">July&nbsp;30, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465920092372/tm2027083d1_8k.htm" STYLE="-sec-extract: exhibit">August&nbsp;10, 2020</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465920131313/tm2037443d1_8k.htm" STYLE="-sec-extract: exhibit">December&nbsp;2, 2020</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465921002681/tm212263d1_8k.htm" STYLE="-sec-extract: exhibit">January&nbsp;11, 2021</A>; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000095012307007844/y32191ae8va12b.htm" STYLE="-sec-extract: exhibit">The description of our common stock contained in our registration statement on Form&nbsp;8-A (File No.&nbsp;001-33497) filed on May&nbsp;23, 2007, under the Exchange Act, including any amendment or report filed for the purpose of updating such description.</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also incorporate by reference any future filings (except
as specifically enumerated above, other than any filings or portions of such reports that are not deemed &ldquo;filed&rdquo; under
the Exchange Act in accordance with the Exchange Act and applicable SEC rules, including current reports furnished under Item 2.02
or Item 7.01 of Form&nbsp;8-K and exhibits filed on such form that are related to such items unless such Form&nbsp;8-K expressly
provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act, including
those made after the date of the initial filing of the registration statement of which this prospectus forms a part, until the
selling stockholders identified herein sell all of the common stock covered by this prospectus and will become a part of this prospectus
from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information
provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any
information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference
to the extent that statements in the later filed document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To obtain copies of these filings, see &ldquo;Where You Can
Find More Information&rdquo; on page&nbsp;11 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2,554,999 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm214628d3_s3asrimg001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>February 2, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant will pay all reasonable expenses incident to
the registration of the shares other than any commissions and discounts of underwriters, dealers or agents. Such expenses are set
forth in the following table. All of the amounts shown are estimates except the SEC registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount<BR>
to
be Paid </B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,336.68</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Printing fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Legal fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accounting fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Miscellaneous fees and expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">65,336.68</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section&nbsp;102 of the Delaware General Corporation Law permits
a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary
damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to
act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved
a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant's restated certificate
of incorporation provides that no director of the Registrant shall be personally liable to it or its stockholders for monetary
damages for any breach of fiduciary duty as director, notwithstanding any provision of law imposing such liability, except to the
extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors for breaches
of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section&nbsp;145 of the Delaware General Corporation Law provides
that a corporation has the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact
that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred
by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason
of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the
best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct
was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made
with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless
and only to the extent that the Delaware Court of Chancery or other adjudicating court determines that, despite the adjudication
of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for
such expenses which the Delaware Court of Chancery or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant's restated certificate of incorporation provides
that the Registrant will, to the fullest extent permitted by Section&nbsp;145 of the Delaware General Corporation Law and the Registrant's
by-laws (each as amended from time to time), indemnify each person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason
of the fact that he or she is or was, or has agreed to become, a director or officer of the Registrant, or is or was serving, or
has agreed to serve, at the request of the Registrant, as a director, officer, partner, or trustee of, or in a similar capacity
with, another corporation, partnership, joint venture, trust or other enterprise, including any employee benefit plan (all such
persons being referred to hereafter as an &ldquo;Indemnitee&rdquo;), or by reason of any action alleged to have been taken or omitted
in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and
reasonably incurred by, or on behalf of, the Indemnitee in connection with such action, suit or proceeding and any appeal therefrom.
Such indemnification may include payment by the Registrant of expenses in defending an action or proceeding in advance of the final
disposition of such action or proceeding upon receipt of an undertaking by the Indemnitee (such undertaking acceptable by the Registrant
without reference to the financial ability of the Indemnitee) to repay such payment if it is ultimately determined that the Indemnitee
is not entitled to indemnification under the Registrant's restated certificate of incorporation; however, the Registrant will not
indemnify any person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person, unless
such initiation was approved by the Registrant's board of directors. Also, the indemnification rights provided in the Registrant's
restated certificate of incorporation (i)&nbsp;are not exclusive of any other rights to which those indemnified may be entitled
under any law, agreement or vote of stockholders or disinterested directors or otherwise, and (ii)&nbsp;will inure to the benefit
of the heirs, executors and administrators of such persons. The Registrant may, to the extent authorized from time to time by its
board of directors, grant indemnification rights to other employees of the Registrant or other persons serving the Registrant and
such rights may be equivalent to, or greater or less than, those set forth in the Registrant's restated certificate of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant has entered into indemnification agreements with
each of its directors. These agreements, among other things, require the Registrant to indemnify each director to the fullest extent
permitted by Delaware law, including indemnification of expenses such as attorneys' fees, judgments, fines and settlement amounts
incurred by the director in any action or proceeding, including any action or proceeding by or in right of the Registrant, arising
out of the person's services as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant maintains a general liability insurance policy
that covers certain liabilities of the Registrant's directors and officers arising out of claims based on acts or omissions in
their capacities as directors or officers. In any underwriting agreement that the Registrant enters into in connection with the
sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, the Registrant,
its directors, its officers and persons who control the Registrant within the meaning of the Securities Act, against certain liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 16. EXHIBITS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt; width: 6%"><B>Exhibit</B></TD>
    <TD STYLE="text-align: right; padding-bottom: 1pt; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt; text-align: center; width: 93%"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000119312512085717/d299897dex31.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000119312512085717/d299897dex31.htm" STYLE="-sec-extract: exhibit">Restated Certificate of Incorporation of the Registrant
(incorporated by reference to Exhibit&nbsp;3.1 of the Registrant's Annual Report on Form&nbsp;10-K filed with the SEC on February&nbsp;28,
2012).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465915044580/a15-13880_1ex3d1.htm" STYLE="-sec-extract: exhibit">3.2</A></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465915044580/a15-13880_1ex3d1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to the Registrant's Restated
Certificate of Incorporation (incorporated by reference to Exhibit&nbsp;3.1 of the Registrant's Current Report on Form&nbsp;8-K
filed with the SEC on June&nbsp;10, 2015).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465918039068/a18-15070_1ex3d1.htm" STYLE="-sec-extract: exhibit">3.3</A></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000110465918039068/a18-15070_1ex3d1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to the Registrant's Restated
Certificate of Incorporation (incorporated by reference to Exhibit&nbsp;3.1 of the Registrant's Current Report on Form&nbsp;8-K
filed with the SEC on June&nbsp;8, 2018).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv3w4.htm" STYLE="-sec-extract: exhibit">3.4</A></TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv3w4.htm" STYLE="-sec-extract: exhibit">Restated By-laws of the of the Registrant (incorporated
by reference to Exhibit&nbsp;3.4 of the Registrant's Registration Statement on Form&nbsp;S-1/A (Registration No.&nbsp;333-141700),
as amended, originally filed with the SEC on April&nbsp;27, 2007)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000110465916098580/a16-4879_1ex10d1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000110465916098580/a16-4879_1ex10d1.htm" STYLE="-sec-extract: exhibit">Note and Warrant Purchase Agreement, dated as of February&nbsp;19,
2016 (incorporated by reference to Exhibit&nbsp;10.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed with the
SEC on February&nbsp;19, 2016).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000110465916130493/a16-14342_1ex10d2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000110465916130493/a16-14342_1ex10d2.htm" STYLE="-sec-extract: exhibit">Joinder to and Amendment of Note and Warrant Purchase
Agreement, dated as of June&nbsp;30, 2016 (incorporated by reference to Exhibit&nbsp;10.2 of the Registrant&rsquo;s Current Report
on Form&nbsp;8-K filed with the SEC on July&nbsp;1, 2016.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000110465916098580/a16-4879_1ex4d1.htm" STYLE="-sec-extract: exhibit">4.3</A></TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000110465916098580/a16-4879_1ex4d1.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Warrant to Purchase Common Stock (incorporated
by reference to Exhibit&nbsp;4.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed with the SEC on February&nbsp;22,
2016).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000110465916130493/a16-14342_1ex4d1.htm" STYLE="-sec-extract: exhibit">4.4</A></TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000110465916130493/a16-14342_1ex4d1.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Warrant to Purchase Common Stock (incorporated
by reference to Exhibit&nbsp;4.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed with the SEC on July&nbsp;1,
2016).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000095012307007596/y32191a2exv4w1.txt" STYLE="-sec-extract: exhibit">4.5</A></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1178879/000095012307007596/y32191a2exv4w1.txt" STYLE="-sec-extract: exhibit">Specimen Stock Certificate evidencing shares of common
stock (incorporated by reference to Exhibit 4.1 of the Registrant&rsquo;s Registration Statement on Form S-1/A (Registration No.
333-141700), as amended, originally filed with the SEC on May 17, 2007)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="tm214628d3_ex5-1.htm" STYLE="-sec-extract: exhibit">5.1</A></TD>
    <TD STYLE="text-align: right; font-size: 10pt"><A HREF="tm214628d3_ex5-1.htm" STYLE="-sec-extract: exhibit">*</A></TD>
    <TD><A HREF="tm214628d3_ex5-1.htm" STYLE="-sec-extract: exhibit">&nbsp;Opinion of Troutman Pepper Hamilton Sanders LLP</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="tm214628d3_ex23-1.htm" STYLE="-sec-extract: exhibit">23.1</A></TD>
    <TD STYLE="text-align: right; font-size: 10pt"><A HREF="tm214628d3_ex23-1.htm" STYLE="-sec-extract: exhibit">*</A></TD>
    <TD><A HREF="tm214628d3_ex23-1.htm" STYLE="-sec-extract: exhibit">&nbsp;Consent of Ernst&nbsp;&amp; Young LLP,&nbsp;Independent
Registered Public Accounting Firm</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="tm214628d3_ex5-1.htm" STYLE="-sec-extract: exhibit">23.2</A></TD>
    <TD STYLE="text-align: right; font-size: 10pt"><A HREF="tm214628d3_ex5-1.htm" STYLE="-sec-extract: exhibit">* </A></TD>
    <TD><A HREF="tm214628d3_ex5-1.htm" STYLE="-sec-extract: exhibit">&nbsp;Consent of Troutman Pepper Hamilton Sanders LLP (included
in Exhibit&nbsp;5.1 to this Registration Statement)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="#sign_001">24.1</A></TD>
    <TD STYLE="text-align: right; font-size: 10pt"><A HREF="#sign_001">* </A></TD>
    <TD STYLE="font-size: 10pt"><A HREF="#sign_001">&nbsp;Power of Attorney (included on the signature page&nbsp;hereto)</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">* Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 17. UNDERTAKINGS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(1)&nbsp;to file, during any period in which offers
or sales are being made, a post-effective amendment to this registration statement: (i)&nbsp;to include any prospectus required
by Section&nbsp;10(a)(3)&nbsp;of the Securities Act; (ii)&nbsp;to reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in volume and
price represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement; and (iii)&nbsp;to include any material information with respect to the
plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration
statement; <I>provided, however</I>, that paragraphs (i), (ii)&nbsp;and (iii)&nbsp;do not apply if the registration statement is
on Form&nbsp;S-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in
reports filed with or furnished to the SEC by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of the Exchange
Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to
Rule&nbsp;424(b)&nbsp;that is part of the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(2)&nbsp;that, for the purpose of determining any
liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(3)&nbsp;to remove from registration by means of a
post-effective amendment any of the securities being registered which remain unsold at the termination of the offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(4)&nbsp;that, for the purpose of determining liability
under the Securities Act to any purchaser: (A)&nbsp;each prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3)&nbsp;shall
be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration
statement; and (B)&nbsp;each prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5)&nbsp;or (b)(7)&nbsp;as part
of a registration statement in reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii)&nbsp;or
(x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a)&nbsp;of the Securities Act shall be deemed
to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after
effectiveness or the date of the first contract of sale of securities in the offering described in prospectus. As provided in Rule&nbsp;430B,
for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new
effective date of the registration statement relating to the securities in the registration statement to which the prospectus relates,
and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof; <I>provided,
however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement or made
in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in
any such document immediately prior to such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;The undersigned registrant hereby undertakes that,
for purposes of determining any liability under the Securities Act, each filing of registrant&rsquo;s annual report pursuant to
Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d)&nbsp;of the Exchange Act that is incorporated by reference in this registration statement
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions
described under Item 15 above, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="sign_001"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933,
as amended, the registrant, Amicus Therapeutics,&nbsp;Inc., certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form&nbsp;S-3 and has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the township of Philadelphia, Pennsylvania, on the 2nd day of February, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt"><B>Amicus Therapeutics,&nbsp;Inc.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">/s/ <FONT STYLE="text-transform: uppercase">John
    F. Crowley</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 43%; padding: 0.25pt"><FONT STYLE="font-size: 10pt">John F. Crowley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt"><I>Chairman and Chief Executive Officer</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We, the undersigned officers and directors of Amicus Therapeutics,&nbsp;Inc.,
hereby severally constitute and appoint John F. Crowley and Daphne Quimi, and all or any one of them, our true and lawful attorneys-in-fact
and agents, with full power of substitution and re-substitution in for him and in his name, place and stead, and in any and all
capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and any subsequent
registration statements pursuant to Rule&nbsp;462 of the Securities Act of 1933, as amended, and to file the same, with all exhibits
thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to
be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and
confirming all that each of said attorneys-in-fact or his substitute or substitutes, may lawfully do or cause to be done by virtue
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933,
as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 34%; text-align: center; font-size: 10pt"><B>Signature</B></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 32%; text-align: center; font-size: 10pt"><B>Title</B></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 32%; text-align: center; font-size: 10pt"><B>Date</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ JOHN F. CROWLEY</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Chairman and Chief Executive Officer</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">John F. Crowley</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">(Principal Executive Officer)</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ DAPHNE QUIMI</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Chief Financial Officer</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Daphne Quimi</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">(Principal Financial Officer)</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ SAMANTHA PROUT</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Vice President, Finance</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Samantha Prout</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">(Principal Accounting Officer)</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ BURKE W. WHITMAN</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Burke Whitman</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ ROBERT ESSNER</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Robert Essner</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ LYNN D. BLEIL</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Lynn D. Bleil</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ MARGARET G. MCGLYNN, R.PH.</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Margaret G. McGlynn, R.PH.</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ MICHAEL G. RAAB</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Michael G. Raab</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ GLEN P. SBLENDORIO</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt"><U></U>Glen P. Sblendorio</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ CRAIG A. WHEELER</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Craig A. Wheeler</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ BRADLEY L. CAMPBELL</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">February 2, 2021</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Bradley L. Campbell</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">/s/ MICHAEL A. KELLY</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">Director</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">February 2, 2021</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">Michael A. Kelly</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm214628d3_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Troutman Pepper Hamilton Sanders LLP</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">400 Berwyn Park, 899 Cassatt Road</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Berwyn, PA 19312-1183</FONT></P></TD>
    <TD STYLE="text-align: right; width: 46%"><IMG SRC="tm214628d3_ex5-1img001.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">troutman.com</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">February 2, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amicus Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3675 Market Street <BR>
Philadelphia, PA 19104</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Re:</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities Registered under Registration Statement on Form&nbsp;S-3</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We have acted as counsel
to Amicus Therapeutics,&nbsp;Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the Company&rsquo;s
registration statement on Form&nbsp;S-3 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;), including the prospectus that
is part of the Registration Statement (the &ldquo;<B><I>Prospectus</I></B>&rdquo;<I>),</I> filed on the date hereof, with the U.S.
Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;), under the Securities Act of 1933, as amended (the
 &ldquo;<B><I>Securities Act</I></B>&rdquo;). The Prospectus provides for the registration of 2,554,999 shares (the &ldquo;<B><I>Shares</I></B>&rdquo;)
of the Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), underlying warrants
(the &ldquo;<B><I>Warrants</I></B>&rdquo;), which Common Stock may be sold from time to time by certain securityholders of the
Company identified therein as selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We have reviewed the
corporate proceedings taken by the Company with respect to the registration of the Shares. We have also examined and relied upon
originals or copies of such corporate records, documents, agreements or other instruments of the Company, and such certificates
and records of public officials, and such other papers, as we have deemed necessary or appropriate in connection herewith, including,
but not limited to, the Company&rsquo;s Restated Certificate of Incorporation, as amended, the Company&rsquo;s Amended and Restated
By-laws, the Warrants and the agreements pursuant to which the Warrants were purchased by the selling stockholders. As to all matters
of fact (including, without limitation, factual conclusions and characterizations and descriptions of purpose, intention or other
state of mind) we have relied entirely upon a certificate of an officer of the Company, and have assumed, without independent inquiry,
the accuracy of that certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In rendering this opinion,
we have assumed the genuineness and authenticity of all signatures on original documents; the legal capacity of all natural persons;
the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as
certified or photocopies; the accuracy and completeness of all documents and records reviewed by us; the accuracy, completeness
and authenticity of certificates issued by any governmental official, office or agency and the absence of change in the information
contained therein from the effective date of any such certificate; and the due authorization, execution and delivery of all documents
where authorization, execution and delivery are prerequisites to the effectiveness of such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm214628d3_ex5-1img001.jpg" ALT=""></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We express no opinion
herein as to the law of any state or jurisdiction other than the laws of the State of Delaware, including statutory provisions
and all applicable provisions of the Delaware Constitution and reported judicial decisions interpreting such laws of the State
of Delaware, and the federal laws of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Based upon the foregoing,
we are of the opinion that, as of the date hereof, the Shares have been duly authorized, and when issued and paid for in accordance
with the terms of the Warrants, will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We assume no obligation
to supplement this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change
the opinion expressed herein after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We hereby consent to
the filing of this opinion as a part of the Registration Statement and to the reference of our firm under the caption &ldquo;Legal
Matters&rdquo; in the Prospectus. In giving such consent, we do not hereby admit that we are in the category of persons whose consent
is required under Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations of the Commission. Except as otherwise
set forth herein, this opinion may not be used, circulated, quoted or otherwise referred to for any purpose or relied upon by any
other person without the express written permission of this firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Troutman Pepper Hamilton Sanders LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Troutman Pepper Hamilton Sanders LLP</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm214628d3_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the reference to our firm
under the caption &quot;Experts&quot; in this Registration Statement (Form&nbsp;S-3) and related Prospectus of Amicus Therapeutics
Inc. for the registration for resale an aggregate of 2,554,999 shares of common stock and to the incorporation by reference therein
of our reports dated March&nbsp;2, 2020, with respect to the consolidated financial statements of Amicus Therapeutics Inc., and
the effectiveness of internal control over financial reporting of Amicus Therapeutics Inc., included in its Annual Report (Form&nbsp;10-K)
for the year ended December&nbsp;31, 2019, filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Ernst&nbsp;&amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Iselin, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January&nbsp;29, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt"></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm214628d3_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm214628d3_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !& )X# 2(  A$! Q$!_\0
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M$?M@7?[%/P2L/%-CH=OKUSJ.L1:2D,]RT*1;X9Y?,)"DMCR<;>/O9SQ@^E_
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M!@+SG\2[]L#]F/5_^"4WB3P;XP^'7CCQ!)::E>20S6URX7YHPK['"826-U+
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M*-?%GP/I_C"^_:4L?#^JZK:QWT>C274D1@WKO$<B0VWDJV" 0 0#P3Q7<_\
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M\G_X.=O"^O6/PF_9@T7Q-JBZMXGBM+JRU74MH O+P0V233855'S2;FP% YX
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MZ&N$_P"#N"2$_![X,Q<&[;6M0* #DKY$0/ZE:^6O^",'PA_:^M/V?O$_C_\
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M! 20.<\5^XG[-G_)NO@'_L7-._\ 2:.OB3_@K+_P3'^,7[?/[%'P?\&6.O\
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<V+Q57$UI5Z[O*6K84445D<X4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm214628d3_s3asrimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm214628d3_s3asrimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "' 6L# 2(  A$! Q$!_\0
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MJ^.P]&=9VI)R]-?R/KJV(ITE>I)+U=CU17%-9L'I^E?*=K_P6E_9OGN8(O\
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MQ&"AMV1^X'_!/G]H^W_:L_9+\)^,()DDN;JT6"\ ;/EW$8"NI]^ ?QK\,?\
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M@;=> _V>-/U5M*O6G\3M]M>9+9VW)_" 0.1@GI7TMX2^"/BSQM>A-/T*^;+
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M"_@K3XU":/91Q32;<&>7 ,CGW8\UZY%T&:_F#B3-99CF$\1)_P"1_0W#N5K
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MG9:OI6G?:M/ND!(C=I%R,_,,^@!S59;4PSPTH<MY\W\UM S2CB')2OH:'_!
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MZ@5ZGX9_:TU;3/\ @C]:_%*1S-K4?A,SL[9.9@QAWYZDY&[ZU\W?M1?M&?M
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MJ:1H_@SXBS?$?PW9(6L+Z9@9(87FF=$;DD8!V\_\\Z^3;O\ ;>^+GB#X*_\
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MN$8*.P4445104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
